nach oben

Medical Oncology

Erschienen in:

01.06.2010 | Original Paper

Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin

verfasst von: Guo-Qing Chen, Zhi-Wei Zhao, Hong-Ying Zhou, Yuan-Jie Liu, Hui-Jun Yang

Erschienen in: Medical Oncology | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Multidrug resistance remains a major clinical obstacle to successful treatment of breast cancer and leads to poor prognosis for the patients. Recently studies have shown that microRNAs play an important role in breast cancer cell resistance to chemotherapeutic agents. In this study, microRNA expression profiles of MCF-7/AdrVp and MCF-7 were analyzed using microarray and the results were confirmed by real-time RT-polymerase chain reaction. Gene Ontology (GO) and pathways mapping tools were employed to analyse systemically the biological processes and signaling pathways affected by differential expression microRNAs. Here, we showed that 181 human microRNAs were differentially expressed between two cell lines. Compared to MCF-7 cells, there were 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF-7/AdrVp. Western blot confirmed the correlation between specific microRNA expression and corresponding changes in protein levels of their targets, specifically those that have a documented role in cancer drug resistance. Furthermore, we validated that signaling pathway highlighted in the study was involved in drug resistance. These results indicated that breast cancer cell resistant to chemotherapy was associated with a group of microRNAs. GO and pathway mapping are valid and effective approach to analyse the function of microRNAs and the results could be a guideline for further investigation.

Nur mit Berechtigung zugänglich

Fojo T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist Updat. 2007;10(1–2):59–67. doi:10.1016/j.drup.2007.02.002.CrossRefPubMed

Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97. doi:10.1016/S0092-8674(04)00045-5.CrossRefPubMed

Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005;433(7027):769–73. doi:10.1038/nature03315.CrossRefPubMed

Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell. 2005;122(1):6–7. doi:10.1016/j.cell.2005.06.036.CrossRefPubMed

O’Rourke JR, Swanson MS, Harfe BD. MicroRNAs in mammalian development and tumorigenesis. Birth Defects Res C Embryo Today. 2006;78(2):172–9. doi:10.1002/bdrc.20071.CrossRefPubMed

Zhang B, Pan X, Cobb GP, Anderson TA. MicroRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302(1):1–12. doi:10.1016/j.ydbio.2006.08.028.CrossRefPubMed

Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857–66. doi:10.1038/nrc1997.CrossRefPubMed

Chen CZ. MicroRNAs as oncogenes and tumor suppressors. N Engl J Med. 2005;353(17):1768–71. doi:10.1056/NEJMp058190.CrossRefPubMed

Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. Oncogene. 2007;26(19):2799–803. doi:10.1038/sj.onc.1210083.CrossRefPubMed

10.

Meng F, Henson R, Lang M, et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology. 2006;130(7):2113–29. doi:10.1053/j.gastro.2006.02.057.CrossRefPubMed

11.

Meng F, Henson R, Wehbe-Janek H, et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133(2):647–58. doi:10.1053/j.gastro.2007.05.022.CrossRefPubMed

12.

Blower PE, Chung JH, Verducci JS, et al. MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther. 2008;7(1):1–9. doi:10.1158/1535-7163.MCT-07-0573.CrossRefPubMed

13.

Weidhaas JB, Babar I, Nallur SM, et al. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res. 2007;67(23):11111–6. doi:10.1158/0008-5472.CAN-07-2858.CrossRefPubMed

14.

Rossi L, Bonmassar E, Faraoni I. Modification of miR gene expression pattern in human colon cancer cells following exposure to 5-fluorouracil in vitro. Pharmacol Res. 2007;56(3):248–53. doi:10.1016/j.phrs.2007.07.001.CrossRefPubMed

15.

Nakajima G, Hayashi K, Xi Y, et al. Non-coding microRNAs hsa-let-7g and hsa-miR-181b are associated with chemoresponse to S-1 in colon cancer. Cancer Genomics Proteomics. 2006;3(5):317–24.PubMed

16.

Chen YN, Mickley LA, Schwartz AM, et al. Characterization of doxorubicin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J Biol Chem. 1990;265(17):10073–80.PubMed

17.

Schmittgen TD, Lee EJ, Jiang J, et al. Real-time PCR quantification of precursor and mature microRNA. Methods. 2008;44(1):31–8. doi:10.1016/j.ymeth.2007.09.006.CrossRefPubMed

18.

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 2001;25(4):402–8.CrossRefPubMed

19.

Gusev Y. Computational methods for analysis of cellular functions and pathways collectively targeted by differentially expressed microRNA. Methods. 2008;44(1):61–72. doi:10.1016/j.ymeth.2007.10.005.CrossRefPubMed

20.

Huang da W, Sherman BT, Tan Q, et al. DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res. 2007;35(Web Server issue):W169–75.CrossRefPubMed

21.

Draghici S, Khatri P, Tarca AL, et al. A systems biology approach for pathway level analysis. Genome Res. 2007;17(10):1537–45. doi:10.1101/gr.6202607.CrossRefPubMed

22.

Nam S, Kim B, Shin S, Lee S. miRGator: an integrated system for functional annotation of microRNAs. Nucleic Acids Res. 2008;36(Database issue):D159–64.PubMed

23.

Welch C, Chen Y, Stallings RL. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene. 2007;26(34):5017–22. doi:10.1038/sj.onc.1210293.CrossRefPubMed

24.

Takagi S, Nakajima M, Mohri T, Yokoi T. Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J Biol Chem. 2008;283(15):9674–80. doi:10.1074/jbc.M709382200.CrossRefPubMed

25.

Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell. 2005;120(5):635–47. doi:10.1016/j.cell.2005.01.014.CrossRefPubMed

26.

Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA. 1998;95(26):15665–70. doi:10.1073/pnas.95.26.15665.CrossRefPubMed

27.

Bandrés E, Cubedo E, Agirre X, et al. Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer. 2006;5:29. doi:10.1186/1476-4598-5-29.CrossRefPubMed

28.

Woods K, Thomson JM, Hammond SM. Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors. J Biol Chem. 2007;282(4):2130–4. doi:10.1074/jbc.C600252200.CrossRefPubMed

29.

Hayashita Y, Osada H, Tatematsu Y, et al. A polycistronic microRNA cluster, miR-17–92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 2005;65(21):9628–32. doi:10.1158/0008-5472.CAN-05-2352.CrossRefPubMed

30.

Michael MZ, O’ Connor SM, van Holst Pellekaan NG, et al. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res. 2003;1(12):882–91.PubMed

31.

Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65(16):7065–70. doi:10.1158/0008-5472.CAN-05-1783.CrossRefPubMed

32.

Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 2006;103(7):2257–61. doi:10.1073/pnas.0510565103.CrossRefPubMed

33.

Adams BD, Furneaux H, White BA. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol. 2007;21(5):1132–47. doi:10.1210/me.2007-0022.CrossRefPubMed

34.

Chédotal A, Kerjan G, Moreau-Fauvarque C. The brain within the tumor: new roles for axon guidance molecules in cancers. Cell Death Differ. 2005;12(8):1044–56. doi:10.1038/sj.cdd.4401707.CrossRefPubMed

35.

Chédotal A. Chemotropic axon guidance molecules in tumorigenesis. Prog Exp Tumor Res. 2007;39:78–90. doi:10.1159/000100048.CrossRefPubMed

36.

Yoo YA, Kim YH, Kim JS, Seo JH. The functional implications of Akt activity and TGF-beta signaling in tamoxifen-resistant breast cancer. Biochim Biophys Acta. 2008;1783(3):438–47. doi:10.1016/j.bbamcr.2007.12.001.CrossRefPubMed

37.

Normanno N, Campiglio M, Maiello MR, et al. Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling. Breast Cancer Res Treat. 2008;112(1):25–33. doi:10.1007/s10549-007-9830-2.CrossRefPubMed

38.

Nahta R, Yuan LX, Zhang B, et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005;65(23):11118–28. doi:10.1158/0008-5472.CAN-04-3841.CrossRefPubMed

39.

Bender LM, Nahta R. Her2 cross talk and therapeutic resistance in breast cancer. Front Biosci. 2008;13:3906–12. doi:10.2741/2978.CrossRefPubMed

40.

Tsuruo T, Naito M, Tomida A, et al. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci. 2003;94(1):15–21. doi:10.1111/j.1349-7006.2003.tb01345.x.CrossRefPubMed

41.

Wendel HG, Malina A, Zhao Z, et al. Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res. 2006;66(15):7639–46. doi:10.1158/0008-5472.CAN-06-0419.CrossRefPubMed

Titel: Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin
verfasst von: Guo-Qing Chen
Zhi-Wei Zhao
Hong-Ying Zhou
Yuan-Jie Liu
Hui-Jun Yang
Publikationsdatum: 01.06.2010
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 2/2010
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-009-9225-9

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2010

Primary colorectal lymphoma

Risk stratification for recurrence in patients with esophageal and junctional carcinoma treated with neoadjuvant chemotherapy and surgery

Glucose metabolism disorders in cancer patients in a Chinese population

Salvage chemotherapy with amrubicin and platinum for relapsed thymic carcinoma: experience in six cases

Immunohistochemical detection of the Raf kinase inhibitor protein in nonneoplastic gastric tissue and gastric cancer tissue

Twilight effects of low doses of ionizing radiation on cellular systems: a bird’s eye view on current concepts and research

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie